Hims & Hers Health, Inc. (HIMS)
NYSE · San Francisco, California, USA · Founded 2017 · CEO Andrew Dudum
Valuation summary
$21.36 fair value versus $16.02 in the market, a difference of +33.3%. Rated Strong Buy.
| Fair value per share | $21.36 |
| Current share price | $16.02 |
| Upside / downside | +33.3% |
| Bear case | $11.75 |
| Bull case | $35.07 |
| Discount rate (WACC) | 11.9% |
| Terminal growth | 2.80% |
| Market capitalisation | $4B |
| EV / Sales | 1.6x |
About Hims & Hers Health, Inc.
Founded in 2017 by Andrew Dudum, who is chief executive. Hims & Hers is an online health company: customers consult a clinician through its app and receive treatments by post on subscription, for hair loss, sexual health, skin, mental health and weight loss. Selling its own lower-priced versions of popular weight-loss injections drove very fast growth and also brought disputes with drug makers and regulators. It has expanded into Europe by buying the online clinic Zava.
Investment case
- More than two million subscribers and a strong consumer brand.
- Personalised treatments are harder for pharmacies to copy.
- Profitable, with new categories such as hormone health and lab testing.
Key risks
- Its weight-loss business depends on rules about compounded drugs that keep changing.
- Large marketing spending is needed to keep adding customers.
- Drug makers now sell directly to patients at lower prices.
Revenue by segment
| Online subscriptions | 97% |
| Wholesale | 3% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $3.7B | $0.2B |
| Year 2 | $4.6B | $0.3B |
| Year 3 | $5.5B | $0.4B |
| Year 4 | $6.3B | $0.5B |
| Year 5 | $6.9B | $0.6B |
What the street says
A divisive stock: fans see a consumer health platform, critics a business built on a regulatory gap.
Comparable companies: HUM · TEM · ALNY · MDLN · NTRA · DXCM · GEHC · BSX
Open the interactive model, price chart and sensitivity grid →